Javier M. Puente - Publications

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

Journal: The New England journal of medicine

Published: July 22, 2026

Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 21, 2026

Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 31, 2025

Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease.

Journal: Journal of clinical medicine

Published: September 29, 2025

Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 25, 2025

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: August 11, 2025

Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients.

Journal: Oncoimmunology

Published: August 08, 2025

SEOM-SOGUG clinical guideline for urothelial cancer (2025).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 29, 2025

Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.

Journal: Medicina (Kaunas, Lithuania)

Published: March 16, 2025

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Journal: Cell reports. Medicine

Published: February 22, 2025

Real-world evidence in localized and locally advanced prostate cancer: applying artificial intelligence to electronic health records.

Journal: BMC cancer

Published: February 10, 2025

Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 03, 2025